Sugi Predict

Sugi Predict / Compounds / SCHEMBL657360

SCHEMBL657360

SCHEMBL657360

Nc1nc2c(nc(Br)n2[C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]1

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ PNP P00491 2/20 0.54
▸ ALDH1A1 P00352 1/20 0.48
▸ MAPT P10636 2/20 0.46
▸ BLM P54132 1/20 0.46
▸ PMP22 Q01453 1/20 0.46
▸ TSHR P16473 1/20 0.46
▸ NFKB1 P19838 1/20 0.46
▸ CYP3A4 P08684 1/20 0.44
▸ ADRB1 P08588 1/20 0.44
▸ DNMT1 P26358 1/20 0.44
▸ POLB P06746 1/20 0.44
▸ PDE7A Q13946 2/20 0.43
▸ PDE7B Q9NP56 2/20 0.43
▸ LMNA P02545 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ TK1 P04183 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20310514 1.00 PNP (0.54) PNPALDH1A1MAPTBLMPMP22
SCHEMBL13351290 1.00 PNP (0.54) PNPALDH1A1MAPTBLMPMP22
SCHEMBL13318964 1.00 PNP (0.54) PNPALDH1A1MAPTBLMPMP22
SCHEMBL14543297 1.00 PNP (0.54) PNPALDH1A1MAPTBLMPMP22
SCHEMBL657361 1.00 PNP (0.54) PNPALDH1A1MAPTBLMPMP22
SCHEMBL10109648 1.00 PNP (0.54) PNPALDH1A1MAPTBLMPMP22
SCHEMBL1401218 0.96 PNP (0.51) PNPALDH1A1MAPTBLMPMP22
SCHEMBL7047708 0.91 ADORA3 (0.54) PNPALDH1A1MAPTBLMPMP22
SCHEMBL655857 0.89 PNP (0.65) PNPMAPTCYP3A4ADRB1DNMT1
SCHEMBL655858 0.89 PNP (0.65) PNPMAPTCYP3A4ADRB1DNMT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4601656-A1 MODIFIED OLIGONUCLEOTIDES Pharmorage Pty Limited (AU) 2025-08-20 — — EP claimed
WO-2024077351-A1 MODIFIED OLIGONUCLEOTIDES Pharmorage Pty Limited (AU) 2024-04-18 — — WO claimed
US-6864049-B1 Method for producing hybridization complexes whose stability is substantially independent of the base composition of two hybridized nucleic acid molecules APPLIGENE-ONCOR S.A. (FR) 2005-03-08 — — US claimed
JP-2000512843-A — — 2000-10-03 — — JP claimed
EP-0954610-A1 METHOD FOR PRODUCING HYBRIDISATION COMPLEXES WHOSE STABILITY IS SUBSTANTIALLY INDEPENDENT OF THE BASE COMPOSITION OF TWO HYBRIDISED NUCLEIC ACID MOLECULES Appligene-Oncor S.A. (FR) 1999-11-10 — — EP claimed
WO-1997049833-A1 METHOD FOR PRODUCING HYBRIDISATION COMPLEXES WHOSE STABILITY IS SUBSTANTIALLY INDEPENDENT OF THE BASE COMPOSITION OF TWO HYBRIDISED NUCLEIC ACID MOLECULES APPLIGENE-ONCOR S.A. (FR) 1997-12-31 — — WO claimed
US-4539205-A Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) 1985-09-03 — — US claimed
WO-2026106815-A1 Z-INDUCING CHIMERA COMPOSITION RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) 2026-05-21 — — WO disclosed
US-12584168-B2 Sample preparation method OXFORD NANOPORE TECHNOLOGIES PLC (GB) 2026-03-24 — — US disclosed
US-20260066042-A1 METHODS AND SYSTEMS FOR HIGH-THROUGHPUT MOLECULAR ANALYSIS OPENTRONS LABWORKS INC (US) 2026-03-05 — — US disclosed
US-20250313889-A1 SAMPLE PREPARATION METHOD OXFORD NANOPORE TECHNOLOGIES PLC (GB) 2025-10-09 — — US disclosed
EP-4601656-A1 MODIFIED OLIGONUCLEOTIDES Pharmorage Pty Limited (AU) 2025-08-20 — — EP disclosed
CN-117343990-B Method and kit for determining target polynucleotide and probe set 牛津纳米孔科技公开有限公司 2025-05-30 — — CN disclosed
WO-1991009130-A1 FERMENTATION PROCESS FOR THE PRODUCTION OF PYRIMIDINE DEOXYRIBONUCLEOSIDES CHEMGEN CORPORATION (US) 1991-06-27 — — WO disclosed
US-4948730-A INDUCING INTERFERON PRODUCTION SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) 1990-08-14 — — US disclosed
US-4849411-A Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) 1989-07-18 — — US disclosed
US-4643992-A Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) 1987-02-17 — — US disclosed
US-4539205-A Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) 1985-09-03 — — US disclosed
EP-0112632-A2 Use of 8-substituted guanine derivatives in the manufacture of a medicament. SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) 1984-07-04 — — EP disclosed
WO-1984001898-A1 MODULATION OF ANIMAL CELLULAR RESPONSES WITH COMPOSITIONS CONTAINNG 8-SUBSTITUTED GUANINE DERIVATIVES SCRIPPS CLINIC RES (US) 1984-05-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12584168-B2 Sample preparation method POLN, POLRMT, POLM PNP 8/4885ALDH1A1 4810/4885MAPT 3486/4885
US-20260066042-A1 METHODS AND SYSTEMS FOR HIGH-THROUGHPUT MOLECULAR ANALYSIS POLRMT, POLL, SARS1 PNP 487/4885ALDH1A1 4286/4885MAPT 968/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.